Palivizumab - Open Access .click

Results 91 to 100 of about 5,796 (217)

Target Trial Emulation and Bias Through Missing Eligibility Data: An Application to a Study of Palivizumab for the Prevention of Hospitalization Due to Infant Respiratory Illness [PDF]

, 2022
Daniel Tompsett +3 more
openalex +1 more source

Cost-Effectiveness Analysis of Maternal Respiratory Syncytial Virus Vaccine in Protecting Infants from RSV Infection in Japan

Infectious Diseases and Therapy
Introduction Respiratory syncytial virus (RSV) is one of the major causes of respiratory tract infections among children. Until recently, the monoclonal antibody palivizumab was the only RSV prophylaxis available in Japan.
Naruhiko Ishiwada +8 more
doaj +1 more source

Evaluation of Reconstituted Lyophilized Palivizumab (Synagis(TM)) Given Intravenously at 15 and 30 mg/kg [PDF]

, 1999
Bernard Landry +4 more
openalex +1 more source

Impact of Palivizumab Guideline Revision on the Incidence of RSV in Children residing in Pediatric Long-term Care Facilities [PDF]

, 2017
Meghan Murray +4 more
openalex +1 more source

Use of palivizumab is underestimated in the Swedish Prescribed Drug Register – implications for register-based drug studies

Clinical Epidemiology, 2014
Marie Linder,1 Camilla Byström,1 Helle Kieler,1 Gunnar Bergman,2 Ann Haerskjold3,4 1Centre for Pharmacoepidemiology, Department of Medicine, Karolinska Institutet, Solna, Stockholm, Sweden; 2Stockholm-Uppsala Department of Pediatric Cardiology ...
Linder M +4 more
doaj

Palivizumab Prophylaxis Against Respiratory Syncytial Virus Infection in Children with Immunocompromised Conditions or Down Syndrome: A Multicenter, Post-Marketing Surveillance in Japan [PDF]